Drug’s unique mechanism of action targets schizophrenia abnormalities

Brain physiology

Newron Pharmaceuticals has reported new findings of mechanism of action that indicate its drug candidate evenamide could be uniquely effective in patients with treatment resistant schizophrenia (TRS).

The drug’s unique mechanism of action targets the core abnormalities in patients with schizophrenia and reduces hippocampal dopaminergic activity, improving symptoms of psychosis, social interactions and cognition.

Long-term, 25% of treated patients treated with evenamide as an add-on therapy met the criteria for remission, a result that Stephen Marder, Distinguished Professor of Psychiatry at the Semel Institute of Neuroscience & Human Behavior, has described as “remarkable and unprecedented”.

The new data was shared at Newron’s investor day in New York City, which featured three leading schizophrenia experts who presented on the unmet medical needs in schizophrenia.

Anthony Grace, Editor-in-Chief, International Journal of Neuropsychopharmacology, Distinguished Professor of Neuroscience, and Professor of Psychiatry and Psychology at the University of Pittsburgh, stated: “Evenamide’s glutamate modulation has produced dramatic effects in the MAM model of schizophrenia, which closely mimics the changes observed in patients with schizophrenia.

“In this model, evenamide reversed abnormal hippocampal neuronal activity, normalised dopamine neuron population activity, improved cognition and normalised social interactions. Its effects on neuronal firing, which persisted well beyond its half-life, indicated that it induces neuronal plasticity and may help with neuronal repair. Furthermore, by acting at the site of pathology, evenamide might also be effective for negative symptoms and cognitive dysfunction.”

Evenamide could have blockbuster potential

A new placebo controlled, one-year trial in patients with TRS who are receiving other antipsychotics is currently in the planning stages with with Dr Marder as the Principal Investigator.

Stefan Weber, Chief Executive Officer of Newron Pharmaceuticals, commented: “We continue to explore all options, including partnering, that could enable us to complete the Phase III clinical development of evenamide, which we believe could have blockbuster potential.”

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free